At close: December 20 at 4:00:00 PM EST
After hours: December 20 at 4:36:38 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 2 | 4 |
| Avg. Estimate | -0.69 | -0.59 | -7.73 | -2.5 |
| Low Estimate | -0.83 | -0.66 | -9.7 | -2.92 |
| High Estimate | -0.42 | -0.52 | -5.75 | -2.16 |
| Year Ago EPS | -- | -- | -- | -7.73 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 4 |
| Avg. Estimate | -- | -- | 521k | 350k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 863k | 1.4M |
| Year Ago Sales | -- | -- | -- | 521k |
| Sales Growth (year/est) | -- | -- | -- | -32.82% |
Earnings History
| Currency in USD | 9/30/2024 |
|---|---|
| EPS Est. | -- |
| EPS Actual | -8.4 |
| Difference | -- |
| Surprise % | -- |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.69 | -0.59 | -7.73 | -2.5 |
| 7 Days Ago | -0.69 | -0.58 | -7.76 | -2.56 |
| 30 Days Ago | -0.82 | -0.54 | -8.59 | -2.41 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| SEPN | -- | -- | -- | 67.67% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Initiated | Cantor Fitzgerald: Overweight | 11/19/2024 |
| Initiated | Wells Fargo: Overweight | 11/19/2024 |
| Initiated | JP Morgan: Overweight | 11/19/2024 |
| Initiated | TD Cowen: Buy | 11/19/2024 |
Related Tickers
MBX MBX Biosciences, Inc.
20.36
+0.44%
BCAX Bicara Therapeutics Inc.
17.59
+5.96%
UPB Upstream Bio, Inc.
16.21
-2.41%
IZTC Invizyne Technologies, Inc.
18.57
-1.49%
APGE Apogee Therapeutics, Inc.
47.71
+1.47%
CGON CG Oncology, Inc.
28.67
+2.32%
ZBIO Zenas BioPharma, Inc.
10.01
+2.56%
CAMP CAMP4 THERAPEUTICS CORPORATION
5.20
-2.62%
IDYA IDEAYA Biosciences, Inc.
25.61
+3.31%
CTNM Contineum Therapeutics, Inc.
13.50
+1.12%